JP2018523484A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523484A5 JP2018523484A5 JP2018509542A JP2018509542A JP2018523484A5 JP 2018523484 A5 JP2018523484 A5 JP 2018523484A5 JP 2018509542 A JP2018509542 A JP 2018509542A JP 2018509542 A JP2018509542 A JP 2018509542A JP 2018523484 A5 JP2018523484 A5 JP 2018523484A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- cell
- nucleic acid
- acid sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 110
- 210000004027 cell Anatomy 0.000 claims description 62
- 150000007523 nucleic acids Chemical group 0.000 claims description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 239000003446 ligand Substances 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 125000006850 spacer group Chemical group 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 19
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 230000020411 cell activation Effects 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 108020004705 Codon Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 230000005754 cellular signaling Effects 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000008045 co-localization Effects 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000001960 triggered effect Effects 0.000 claims description 2
- 239000013638 trimer Substances 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514874.5 | 2015-08-20 | ||
| GBGB1514874.5A GB201514874D0 (en) | 2015-08-20 | 2015-08-20 | Cell |
| PCT/GB2016/052563 WO2017029511A1 (en) | 2015-08-20 | 2016-08-19 | Cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020194900A Division JP2021027841A (ja) | 2015-08-20 | 2020-11-25 | 細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523484A JP2018523484A (ja) | 2018-08-23 |
| JP2018523484A5 true JP2018523484A5 (enExample) | 2019-07-25 |
| JP7395249B2 JP7395249B2 (ja) | 2023-12-11 |
Family
ID=54292002
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018509542A Active JP7395249B2 (ja) | 2015-08-20 | 2016-08-19 | 細胞 |
| JP2020194900A Withdrawn JP2021027841A (ja) | 2015-08-20 | 2020-11-25 | 細胞 |
| JP2023180246A Pending JP2023178386A (ja) | 2015-08-20 | 2023-10-19 | 細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020194900A Withdrawn JP2021027841A (ja) | 2015-08-20 | 2020-11-25 | 細胞 |
| JP2023180246A Pending JP2023178386A (ja) | 2015-08-20 | 2023-10-19 | 細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11365262B2 (enExample) |
| EP (1) | EP3337501A1 (enExample) |
| JP (3) | JP7395249B2 (enExample) |
| CN (1) | CN108135984A (enExample) |
| AU (1) | AU2016308617A1 (enExample) |
| CA (1) | CA2995775A1 (enExample) |
| GB (1) | GB201514874D0 (enExample) |
| HK (1) | HK1250667A1 (enExample) |
| WO (1) | WO2017029511A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| GB201620070D0 (en) * | 2016-11-28 | 2017-01-11 | Autolus Ltd | Signal transduction modifying protein |
| WO2018132506A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| ES3010559T3 (en) | 2017-02-28 | 2025-04-03 | Endocyte Inc | Compositions and methods for car t cell therapy |
| CA3056115A1 (en) * | 2017-03-16 | 2018-09-20 | The General Hospital Corporation | Chimeric antigen receptors targeting cd37 |
| BR112019020001A2 (pt) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| WO2018201088A1 (en) | 2017-04-27 | 2018-11-01 | Washington University | Activation of natural cytotoxicity receptor 2 (ncr2) |
| CN111164203A (zh) * | 2017-08-02 | 2020-05-15 | 奥托路斯有限公司 | 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞 |
| WO2019086394A1 (en) * | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | The compbody - a multivalent target binder |
| US20190192678A1 (en) * | 2017-12-18 | 2019-06-27 | Novather, Inc. | System and method for the treatment of disease using a hyperspecific modified protein system |
| TW201940182A (zh) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| AU2019330347B2 (en) | 2018-08-29 | 2025-07-24 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| SG11202102781UA (en) | 2018-09-27 | 2021-04-29 | Autolus Ltd | Chimeric antigen receptor |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| EP3986442A4 (en) * | 2019-06-21 | 2023-10-25 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| WO2021007580A1 (en) * | 2019-07-11 | 2021-01-14 | Valkyr, Inc. | System and methods relating to chimeric autoantibody receptors |
| CN112779223B (zh) * | 2019-11-08 | 2024-06-11 | 浙江煦顼技术有限公司 | 偶联嵌合抗原受体细胞及其用途 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9206440B2 (en) | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2014145252A2 (en) * | 2013-03-15 | 2014-09-18 | Milone Michael C | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| PL3071222T3 (pl) | 2013-11-21 | 2021-04-19 | Ucl Business Ltd | Komórka |
| US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| ES2939760T3 (es) | 2014-03-15 | 2023-04-26 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico para antígenos |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
-
2015
- 2015-08-20 GB GBGB1514874.5A patent/GB201514874D0/en not_active Ceased
-
2016
- 2016-08-19 WO PCT/GB2016/052563 patent/WO2017029511A1/en not_active Ceased
- 2016-08-19 EP EP16756757.7A patent/EP3337501A1/en active Pending
- 2016-08-19 US US15/753,505 patent/US11365262B2/en active Active
- 2016-08-19 CA CA2995775A patent/CA2995775A1/en not_active Abandoned
- 2016-08-19 HK HK18110271.9A patent/HK1250667A1/zh unknown
- 2016-08-19 CN CN201680046855.5A patent/CN108135984A/zh active Pending
- 2016-08-19 JP JP2018509542A patent/JP7395249B2/ja active Active
- 2016-08-19 AU AU2016308617A patent/AU2016308617A1/en not_active Abandoned
-
2020
- 2020-11-25 JP JP2020194900A patent/JP2021027841A/ja not_active Withdrawn
-
2023
- 2023-10-19 JP JP2023180246A patent/JP2023178386A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018523484A5 (enExample) | ||
| JP2016538855A5 (enExample) | ||
| RU2016124278A (ru) | Клетка | |
| JP2016538854A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| JP7253020B2 (ja) | キメラ抗原受容体およびその使用 | |
| JP2019150066A5 (enExample) | ||
| JP2021035395A5 (enExample) | ||
| JP2021137013A (ja) | 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体 | |
| JP2024086884A (ja) | リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加 | |
| JP2018532407A5 (enExample) | ||
| RU2017121892A (ru) | Клетка | |
| KR102588292B1 (ko) | 항-bcma 키메라 항원 수용체 | |
| JP2018501794A5 (enExample) | ||
| JP2018517410A5 (enExample) | ||
| JP2015518479A5 (enExample) | ||
| JP2024522357A (ja) | クローディン１８．２ｔ細胞－抗原カプラーおよびその使用 | |
| JP2018521663A (ja) | 治療薬 | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| JP2019514393A (ja) | 細胞に基づくネオ抗原ワクチンおよびその使用 | |
| JP7684692B2 (ja) | 低酸素応答性キメラ抗原受容体 | |
| JP2018523484A (ja) | 細胞 | |
| JP2017537622A5 (enExample) | ||
| JP2017513478A5 (enExample) | ||
| CN112638947A (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 |